In the red hot market for pharmaceutical deal-making it's either eat or be eaten. That's the case with Teva Pharmaceutical's $82 a share cash and stock bid for generic competitor Mylan on Tuesday morning, a direct challenge to Mylan...

The post-hearing dead cat bounce in Mylan stock is over. The "blood in the streets" buyers are in trouble as the stock is tumbling following WSJ reports that Mylan is admitting its pre-tax profits for EpiPen are actually 60% higher ...

Diamondback Energy, Inc. (NASDAQ:FANG) and Oasis Petroleum Inc. (NYSE:OAS) were both subjects of two Form 4 filings with the SEC. Diamondback investor Wexford Capital, managed by Charles Davidson, disposed of 1.03 million shares in ...

Shares in Tesaro, a small drug maker, soared 82% in pre-market trading after the company said its experimental medicine, niraparib, slowed the growth of ovarian tumors in a 500-patient clinical trial. Tesaro says that it plans to fi...